Effient News and Research

RSS

Precision medicine can determine the best drug treatment for severe heart disease

Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.

15 May 2020

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel became the mainstay of therapy.

11 Sep 2018

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.

9 Dec 2015

Boca Raton Regional Hospital introduces ultra-minimally invasive procedure for patients with atrial fibrillation

Boca Raton Regional Hospital's Richard G. Cartledge, MD, FACS, has begun performing ultra-minimally invasive left atrial appendage ligation for atrial fibrillation patients who are on anticoagulants such as Coumadin, Xarelto or Effient. Dr. Cartledge, who is Chief of Cardiothoracic Surgery at the Hospital, is one of a select group of surgeons nationally using this method, which involves making two microscopic incisions in order to seal off the left atrial appendage (LAA) in patients where anticoagulants are contraindicated or who refuse to be on such medications.

3 Sep 2015

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).

18 Nov 2014

Most patients taking common blood-thinning drugs may be receiving wrong dosage levels

Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.

8 Nov 2012

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

8 Aug 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

Studies outline dilemmas on new generic heart drugs, hormone replacement therapy

One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.

30 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Aggredyne closes $3 million Series A convertible preferred stock financing

Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function testing, sold out and closed a $3 million Series A convertible preferred stock financing.

23 Apr 2012

The Lancet acknowledges world's first bedside genetic test

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal.

30 Mar 2012

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

The Cardiovascular Research Foundation (CRF) today announced the initiation of the HORIZONS-AMI II randomized trial, evaluating Promus Element platinum-chromium everolimus-eluting stents versus Omega bare-metal stents in patients with heart attack undergoing primary angioplasty with bivalirudin anticoagulation.

28 Mar 2012

CVD/MI complications tend to occur within first 30 days after PCI

Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a balloon-tipped tube into the vessel. Sometimes a stent is also inserted to keep the blood vessel open.

26 Mar 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Experts from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American Heart Association Scientific Sessions 2011 held November 12-16, 2011 in Orlando, Florida.

18 Nov 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry.

10 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.